Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Ovarian Neoplasms

Free Subscription Articles published in J Natl Cancer Inst Retrieve available abstracts of 24 articles: HTML format

Single Articles

February 2026
1. MAJIDI A, Rinaldi S, Truong T, Dossus L, et al
   Pre-diagnosis thyroid dysfunction and ovarian cancer risk and survival: a prospective cohort study.
   J Natl Cancer Inst. 2026 Feb 18:djag055. doi: 10.1093.
   PubMed     Abstract available
   
   
   August 2025
2. MAJIDI A, Rinaldi S, Biessy C, Vozar B, et al
   Thyroid hormones and epithelial ovarian cancer risk and survival: results from the EPIC study.
   J Natl Cancer Inst. 2025 Aug 14:djaf222. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. JONES RR, Madrigal JM, Medgyesi DN, Fisher JA, et al
   Serum concentrations of per- and polyfluoroalkyl substances and risk of ovarian cancer.
   J Natl Cancer Inst. 2025 Aug 1:djaf204. doi: 10.1093.
   PubMed     Abstract available
   
   
   April 2025
4. LI S, Madanat-Harjuoja L, Leslie G, Barnes DR, et al
   Childhood, adolescent, and young adulthood cancer risk in BRCA1 or BRCA2 pathogenic variant carriers.
   J Natl Cancer Inst. 2025;117:728-736.
   PubMed     Abstract available
   
   
   
5. STROOT IAS, Bart J, Hollema H, Wagner MM, et al
   High-grade serous carcinoma occurring after risk-reducing salpingo-oophorectomy in BRCA1/2 germline pathogenic variant carriers.
   J Natl Cancer Inst. 2025;117:719-727.
   PubMed     Abstract available
   
   
   February 2025
6. LEHRER S
   Re: Timing of depression in relation to risk of ovarian cancer.
   J Natl Cancer Inst. 2025 Feb 25:djaf043. doi: 10.1093.
   PubMed    
   
   
   January 2025
7. ROBERTS AL, Townsend MK, Chibnik LB, Kubzansky LD, et al
   Timing of depression in relation to risk of ovarian cancer.
   J Natl Cancer Inst. 2025 Jan 2:djae348. doi: 10.1093.
   PubMed     Abstract available
   
   
   December 2024
8. EVANS DG, Flaum N, Crosbie EJ
   High-grade serous ovarian cancer after bilateral salpingo-oophorectomy.
   J Natl Cancer Inst. 2024 Dec 31:djae328. doi: 10.1093.
   PubMed    
   
   
   
9. ELZE L, van der Post RS, Vos JR, Mensenkamp AR, et al
   Genomic instability in non-breast or ovarian malignancies of individuals with germline pathogenic variants in BRCA1/2.
   J Natl Cancer Inst. 2024;116:1904-1913.
   PubMed     Abstract available
   
   
   November 2024
10. NAROD SA, Gronwald J, Karlan B, Moller P, et al
    Incidence of peritoneal cancer after oophorectomy among BRCA1 and BRCA2 mutation carriers.
    J Natl Cancer Inst. 2024;116:1753-1760.
    PubMed     Abstract available
    
    
    October 2024
11. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1675-1682.
    PubMed     Abstract available
    
    
    August 2024
12. FOULKES WD, Polak P
    Probing the relevance of BRCA1 and BRCA2 germline pathogenic variants beyond breast and ovarian cancer.
    J Natl Cancer Inst. 2024 Aug 22:djae184. doi: 10.1093.
    PubMed    
    
    
    
13. MYERS ER
    Reducing ovarian cancer mortality through screening: an impossible dream?
    J Natl Cancer Inst. 2024 Aug 12:djae175. doi: 10.1093.
    PubMed    
    
    
    
14. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1280-1287.
    PubMed     Abstract available
    
    
    July 2024
15. ISHIZAWA S, Niu J, Tammemagi MC, Irajizad E, et al
    Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework.
    J Natl Cancer Inst. 2024 Jul 23:djae145. doi: 10.1093.
    PubMed     Abstract available
    
    
    
16. ZHENG G, Baandrup L, Wang J, Hertzum-Larsen R, et al
    Ovarian cancer risk factors in relation to family history.
    J Natl Cancer Inst. 2024 Jul 4:djae164. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2024
17. BAKER SG, Etzioni R
    Prediagnostic evaluation of multicancer detection tests: design and analysis considerations.
    J Natl Cancer Inst. 2024;116:795-799.
    PubMed     Abstract available
    
    
    May 2024
18. DAVIS EW, Attwood K, Prunier J, Paragh G, et al
    The association of body composition phenotypes before chemotherapy with epithelial ovarian cancer mortality.
    J Natl Cancer Inst. 2024 May 28:djae112. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2024
19. CAO A, Esserman DA, Cartmel B, Irwin ML, et al
    Association between diet quality and ovarian cancer risk and survival.
    J Natl Cancer Inst. 2024 Feb 23:djae040. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2023
20. PHUNG MT, Lee AW, McLean K, Anton-Culver H, et al
    A framework for assessing interactions for risk stratification models: the example of ovarian cancer.
    J Natl Cancer Inst. 2023 Jul 12:djad137. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2023
21. HURWITZ LM, Dogbe N, Hughes Barry K, Koutros S, et al
    Obesity and prostate cancer screening, incidence, and mortality in the PLCO Cancer Screening Trial.
    J Natl Cancer Inst. 2023 Jun 29:djad113. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. LI S, Nguyen-Dumont T, Southey MC, Hopper JL, et al
    RE: Heterozygous BRCA1 and BRCA2 and mismatch repair gene pathogenic variants in children and adolescents with cancer.
    J Natl Cancer Inst. 2023;115:757-759.
    PubMed    
    
    
    May 2023
23. SHI J, Kraft P, Rosner BA, Benavente Y, et al
    Risk prediction models for endometrial cancer: development and validation in an international consortium.
    J Natl Cancer Inst. 2023;115:552-559.
    PubMed     Abstract available
    
    
    April 2023
24. GUPTA S, Hanna PE, Ouyang T, Yamada KS, et al
    Kidney Function in Patients with Ovarian Cancer Treated with Poly (ADP-ribose) polymerase (PARP) Inhibitors.
    J Natl Cancer Inst. 2023 Apr 19:djad070. doi: 10.1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum